3.2 The incidence of adverse events in subgroup
Subgroup analysis by disease type showed that the highest total adverse event pooled incidence rate of patients with MS at 0.43 (95% CI, 0.31–0.55, I² = 100%). MG and NMOSD of 0.26 (95% CI, 0.15–0.37, I² = 100%), and 0.30 (95% CI, 0.00–0.63, I² = 91%), respectively. (Supplementary Fig.2 ). The pooled incidence rate of adverse reactions following different immunization doses was basically the same, 0.37 (95% CI, 0.25 – 0.49, I² = 100%) after the first dose, 0.34 (95% CI, 0.21 – 0.47, I² = 99%) after the second dose and 0.36 (95% CI, 0.27 – 0.44, I² = 100%) after the third dose (Supplementary Fig.3 ). The pooled incidence rate of adverse events post-vaccination was similar across vaccine types,0.35 (95% CI, 0.23–0.47, I² = 100%) for mRNA vaccines, 0.34 (95% CI, 0.13–0.56, I² = 99%) for inactivated vaccines, and 0.36 (95% CI, 0.19–0.53, I² = 100%) for mixed vaccines (Supplementary Fig.4 ).